Brookline Capital Management Estimates XFOR FY2024 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Analysts at Brookline Capital Management decreased their FY2024 EPS estimates for X4 Pharmaceuticals in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($0.67) per share for the year, down from their previous estimate of ($0.62). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.50) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.16) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at $0.42 EPS.

XFOR has been the topic of a number of other reports. HC Wainwright lowered their price target on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating on the stock in a report on Thursday, November 14th. Stifel Nicolaus dropped their target price on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 14th.

X4 Pharmaceuticals Price Performance

NASDAQ XFOR opened at $0.64 on Thursday. The stock has a market cap of $108.52 million, a price-to-earnings ratio of -7.07 and a beta of 0.14. X4 Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $1.60. The company’s 50 day moving average is $0.55 and its two-hundred day moving average is $0.62. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26.

Hedge Funds Weigh In On X4 Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP purchased a new position in X4 Pharmaceuticals during the 3rd quarter valued at about $340,000. K2 Principal Fund L.P. bought a new position in shares of X4 Pharmaceuticals during the second quarter valued at approximately $284,000. AQR Capital Management LLC boosted its stake in shares of X4 Pharmaceuticals by 1,080.3% during the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after purchasing an additional 388,115 shares in the last quarter. State Street Corp increased its holdings in X4 Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after buying an additional 189,105 shares during the period. Finally, Barclays PLC raised its stake in X4 Pharmaceuticals by 196.0% in the third quarter. Barclays PLC now owns 277,682 shares of the company’s stock worth $185,000 after buying an additional 183,861 shares in the last quarter. 72.03% of the stock is owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.